Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553326/0/en/Werewolf-Therapeutics-Presents-Preclinical-Data-on-mWTX-330-a-Surrogate-IL-12-INDUKINE-Molecule-at-the-Society-for-Immunotherapy-of-Cancer-Annual-Meeting.html

– mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics –

Read more at globenewswire.com

Related news for (HOWL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.